KIT and gastrointestinal stromal tumor: In summary, we have shown that inhibitors of the ubiquitin-proteasome machinery, especially those that inhibit the 20S proteolytic core, have therapeutic activity in imatinib-sensitive and imatinib-resistant KIT-mutant GIST model systems.